Luigi Gargiulo

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 134 publications

Clinical profile, patient experience, and management of vitiligo in Italy: Data from the National 2024 Vitiligo Week Awareness Campaign.

Clinical profile, patient experience, and management of vitiligo in Italy: Data from the National 2024 Vitiligo Week Awareness Campaign.

Journal: JAAD international

Published: August 01, 2026

When Efficacy Meets Value: The Growing Case for IL-23 Inhibitors in Psoriasis.

When Efficacy Meets Value: The Growing Case for IL-23 Inhibitors in Psoriasis.

Journal: International journal of dermatology

Published: July 09, 2026

Therapeutic outcomes of CAL/BDP PAD-based cream in patients with mild-to-moderate psoriasis: insights from four case reports.

Therapeutic outcomes of CAL/BDP PAD-based cream in patients with mild-to-moderate psoriasis: insights from four case reports.

Journal: Drugs in context

Published: May 11, 2026

Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study.

Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study.

Journal: Dermatology and therapy

Published: May 05, 2026

Bullous Pemphigoid Disease Area Index Pruritus, Activity, and Damage During Biologic Therapy in Bullous Pemphigoid: An International Dual-Center Study.

Bullous Pemphigoid Disease Area Index Pruritus, Activity, and Damage During Biologic Therapy in Bullous Pemphigoid: An International Dual-Center Study.

Journal: The Journal of dermatology

Published: April 27, 2026

JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study.

JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study.

Journal: Dermatology and therapy

Published: April 24, 2026

Dose Adjustment of JAK Inhibitors for the Management of Moderate-to-Severe Atopic Dermatitis: A Single-Centre Retrospective Study.

Dose Adjustment of JAK Inhibitors for the Management of Moderate-to-Severe Atopic Dermatitis: A Single-Centre Retrospective Study.

Journal: Medicina (Kaunas, Lithuania)

Published: April 13, 2026

Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.

Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.

Journal: Clinical and experimental dermatology

Published: April 12, 2026

Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.

Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: April 11, 2026

Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis.

Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis.

Journal: Dermatology and therapy

Published: April 10, 2026

Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experience.

Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experience.

Journal: Expert opinion on biological therapy

Published: April 01, 2026

Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort Study.

Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort Study.

Journal: Journal of cutaneous medicine and surgery

Published: March 17, 2026

Showing 1-12 of 134

Last Updated: 09/26/2026